Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 165

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 165
---
R’s business.

<div align='center'>TRADEMARKS, SERVICE MARKS AND TRADENAMES</div>

This prospectus contains trademarks,
service marks and trade names of others, which are the property of their respective owners. Solely for convenience, the trademarks, service
marks, logos and trade names referred to in this prospectus are included without the ® and ™ symbols. All trademarks, service
marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our
use or display of other companies’ trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies or unrelated parties.

<div align='center'>USE OF PROCEEDS</div>

The Company estimates
that the net proceeds to the Company from the issuance and sale of Class A Ordinary Shares in this offering will be approximately $___, based
on an assumed offering price of $___ per ordinary share, after deducting placement agent fees and offering expenses payable by
us.

As of the date of this prospectus,
we intend to use proceeds we receive from the offering for working capital, to support DiamiR’s biopharma services franchise, increase
lab throughput, advance pipeline products, including CogniMIR®, test for glioblastoma and other LDTs under CLIA guidelines, and other
general corporate purposes.

<div align='center'>79</div>

The amounts and timing
of the Company’s actual expenditures will depend upon numerous factors. The Company may also use a portion of the net proceeds to
acquire, license and invest in complementary products, technologies, or additional businesses; however, we currently have no
agreements or commitments with respect to any such transaction.

The foregoing represents the Company’s current intentions based
upon the Company’s present plans and business conditions to allocate and use the net proceeds of this offering. However, the nature,
amounts and timing of the Company’s actual expenditures may vary significantly depending on numerous factors. As a result, the Company’s
management has and will retain broad discretion over the allocation of the net proceeds from this offering. The Companymay find it necessary
or advisable to use the net proceeds from this offering for other purposes, and it will have broad discretion in the application of net
proceeds from this offering. If an unforeseen event occurs or business conditions change, the Company may use the proceeds of this offering
d